Jun 14, 2026 04:35PM
Jun 14, 2026 04:35PM
Jun 4, 2026 08:06AM
Jun 4, 2026 08:05AM
Jul 29, 2025 07:00AM
Jun 20, 2025 04:31PM
Jun 20, 2025 04:30PM Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
Dec 11, 2024 09:44AM
Aug 15, 2024 08:57AM
Feb 27, 2024 04:11PM
Feb 27, 2024 04:08PM
Feb 7, 2023 07:00AM
Nov 1, 2022 07:00AM
Aug 2, 2022 07:00AM Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
May 5, 2022 08:15AM
May 3, 2022 01:25PM
May 3, 2022 07:00AM
Mar 26, 2022 10:40AM
Mar 14, 2022 08:02AM
Mar 14, 2022 08:00AM
Feb 8, 2022 07:00AM Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
Dec 14, 2021 04:31PM
Dec 14, 2021 04:30PM
Nov 2, 2021 07:00AM
Nov 1, 2021 07:03AM
Nov 1, 2021 07:00AM
Sep 1, 2021 12:36PM
Aug 3, 2021 07:00AM Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Jul 16, 2021 10:01AM
Jul 16, 2021 10:00AM
Jul 14, 2021 05:02PM
Jul 14, 2021 05:00PM
Jun 24, 2021 03:30PM
Jun 24, 2021 03:30PM
Jun 22, 2021 12:38PM Incyte (INCY) Briefing Doc on Retifanlimab Suggest Data May Be Insufficient to Support Approval - Mizuho
Jun 11, 2021 10:23AM
Jun 11, 2021 07:30AM
Jun 11, 2021 07:30AM
Jun 8, 2021 07:32AM
Jun 8, 2021 07:30AM
May 4, 2021 07:00AM
Apr 6, 2021 04:30PM Lilly (LLY) and Incyte (INCY) communicate review extension of sNDA for baricitinib for treatment of moderate to severe atopic dermatitis
Apr 6, 2021 04:30PM
Mar 9, 2021 07:48AM
Feb 22, 2021 08:06AM
Feb 22, 2021 08:00AM
Feb 19, 2021 08:02AM
Feb 19, 2021 08:00AM
Jan 21, 2021 04:33PM Incyte (INCY) Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal
Jan 21, 2021 04:30PM

15,447 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All